ProMIS Neurosciences (PMN) Competitors $0.52 -0.02 (-2.80%) As of 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN vs. OKYO, ABOS, FBRX, VHAQ, RPTX, OTLK, ICCC, SKYE, MCRB, and HOWLShould you be buying ProMIS Neurosciences stock or one of its competitors? The main competitors of ProMIS Neurosciences include OKYO Pharma (OKYO), Acumen Pharmaceuticals (ABOS), Forte Biosciences (FBRX), Viveon Health Acquisition (VHAQ), Repare Therapeutics (RPTX), Outlook Therapeutics (OTLK), ImmuCell (ICCC), Skye Bioscience (SKYE), Seres Therapeutics (MCRB), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry. ProMIS Neurosciences vs. Its Competitors OKYO Pharma Acumen Pharmaceuticals Forte Biosciences Viveon Health Acquisition Repare Therapeutics Outlook Therapeutics ImmuCell Skye Bioscience Seres Therapeutics Werewolf Therapeutics OKYO Pharma (NASDAQ:OKYO) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking. Does the media refer more to OKYO or PMN? In the previous week, OKYO Pharma had 2 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 3 mentions for OKYO Pharma and 1 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 1.89 beat OKYO Pharma's score of 0.62 indicating that ProMIS Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment OKYO Pharma Positive ProMIS Neurosciences Very Positive Is OKYO or PMN more profitable? OKYO Pharma's return on equity of 0.00% beat ProMIS Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A ProMIS Neurosciences N/A -636.20%-130.32% Do analysts rate OKYO or PMN? OKYO Pharma presently has a consensus price target of $7.00, indicating a potential upside of 176.68%. ProMIS Neurosciences has a consensus price target of $4.50, indicating a potential upside of 765.38%. Given ProMIS Neurosciences' higher possible upside, analysts clearly believe ProMIS Neurosciences is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ProMIS Neurosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in OKYO or PMN? 3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 6.1% of ProMIS Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, OKYO or PMN? OKYO Pharma has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Which has better earnings & valuation, OKYO or PMN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$16.83MN/AN/AProMIS NeurosciencesN/AN/A-$13.21M-$0.05-10.40 Does the MarketBeat Community believe in OKYO or PMN? OKYO Pharma received 6 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. CompanyUnderperformOutperformOKYO PharmaOutperform Votes11100.00% Underperform VotesNo VotesProMIS NeurosciencesOutperform Votes5100.00% Underperform VotesNo Votes SummaryProMIS Neurosciences beats OKYO Pharma on 6 of the 11 factors compared between the two stocks. Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricProMIS NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.00M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-5.208.6727.1419.96Price / SalesN/A262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book2.606.597.064.69Net Income-$13.21M$143.75M$3.23B$248.14M7 Day Performance8.15%3.72%2.67%2.39%1 Month Performance3.79%11.01%8.82%6.05%1 Year Performance-69.05%3.87%31.44%13.60% ProMIS Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNProMIS Neurosciences2.3819 of 5 stars$0.52-2.8%$4.50+765.4%-68.7%$17.00MN/A-5.205Positive NewsOKYOOKYO Pharma2.1797 of 5 stars$1.87+6.9%$7.00+274.3%+64.9%$63.27MN/A0.007News CoverageGap UpABOSAcumen Pharmaceuticals2.1878 of 5 stars$1.04+4.0%$7.33+605.1%-57.0%$63.00MN/A-0.7520Positive NewsShort Interest ↑Analyst RevisionFBRXForte Biosciences3.014 of 5 stars$9.55+8.2%$61.00+538.7%+54,210.3%$62.87MN/A-0.595Options VolumeGap UpVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeRPTXRepare Therapeutics2.4473 of 5 stars$1.45+5.8%$4.50+210.3%-62.1%$62.19M$1.07M-0.73180Positive NewsOTLKOutlook Therapeutics1.434 of 5 stars$1.85+4.5%$10.20+451.4%-76.5%$62.10MN/A-0.2520News CoverageICCCImmuCell0.5793 of 5 stars$6.87+1.3%N/A+45.6%$62.08M$27.30M-13.7470Short Interest ↓SKYESkye Bioscience1.8148 of 5 stars$2.32+33.9%$16.60+616.8%-78.8%$61.33MN/A-2.7411Positive NewsAnalyst RevisionMCRBSeres Therapeutics3.562 of 5 stars$7.00flat$73.67+952.4%-49.5%$61.12M$126.33M-30.43330Positive NewsHOWLWerewolf Therapeutics3.943 of 5 stars$1.36+13.3%$8.33+512.7%-61.6%$61.03M$1.14M-0.8940Positive NewsGap Up Related Companies and Tools Related Companies OKYO Pharma Alternatives Acumen Pharmaceuticals Alternatives Forte Biosciences Alternatives Viveon Health Acquisition Alternatives Repare Therapeutics Alternatives Outlook Therapeutics Alternatives ImmuCell Alternatives Skye Bioscience Alternatives Seres Therapeutics Alternatives Werewolf Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PMN Stock Free PMN Stock Alerts